AMENDMENT

Kindly amend the application, without prejudice, without admission, without surrender of subject matter, and without any intention of creating any estoppel as to equivalents, as follows:

IN THE CLAIMS:

Please add the following new claims without prejudice, without admission, without surrender of subject matter, and without any intention of creating any estoppel as to equivalents:

--40. (New) A method for enhancing the immunogenicity of a polypeptide encoded by open reading frame (ORF) 1 of porcine circovirus type II (PCV-2), ORF2 of PCV-2, ORF1 of porcine circovirus type I (PCV-1) or ORF2 of PCV-1 expressed *in vivo* in a porcine host by at least one plasmid that encodes and expresses *in vivo* in a porcine host the polypeptide, said method comprising administering the at least one plasmid as a complex with an adjuvant which comprises a cationic lipid of formula



in which R_1 is a saturated or unsaturated linear aliphatic radical having from 12 to 18 carbon atoms, R_2 is aliphatic radical comprising from 2 to 3 carbon atoms, and X is an hydroxyl or amine group.

41. (New) A method for enhancing the immunogenicity of a polypeptide encoded by open reading frame (ORF) 1 of porcine circovirus type II (PCV-2), ORF2 of PCV-2, ORF1 of porcine circovirus type I (PCV-1) or ORF2 of PCV-1 expressed *in vivo* in a porcine host by at least one plasmid that encodes and expresses *in vivo* in a porcine host the polypeptide, said method comprising administering the at least one plasmid with an adjuvant which comprises a carbomer.

42. (New) The method of claim 40 wherein the cationic lipid is N-(2-hydroxyethyl)-N,N-dimethyl-2,3-bis(tetradecyloxy)-1-propanammonium (DMRIE).

43. (New) The method of claim 42 wherein DMRIE is coupled to a neutral lipid.

44. (New) The method of claim 43 wherein DMRIE is coupled to dioleoylphosphatidylethanolamine (DOPE).

45. (New) The method of any one of claims 40 or 41wherein the administering includes admistering a porcine cytokine or a plasmid that encodes and expresses a porcine cytokine.

46. (New) The method of claim 45 wherein the porcine cytokine is GM-CSF.

47. (New) The method according to claim 40 or 41 wherein the administering includes administering a plasmid encoding and expressing an immunogen from a porcine pathogenic agent other than PCV-2 or PCV-1.

48. (New) The method according to any one of claims 40 or 41 wherein the administering includes administering at least one plasmid that contains and expresses ORF1 of PCV-2.

49. (New) The method according to any one of claims 40 or 41 wherein the administering includes administering at least one plasmid that contains and expresses ORF2 of PCV-2.

50. (New) The method according to any one of claims 40 or 41 wherein the administering includes administering at least one plasmid that contains and expresses ORF1 and ORF2 of PCV-2.

51. (New) The method according to any one of claims 40 or 41 wherein the administering includes administering at least one plasmid that contains and expresses ORF1 of PCV-2 and ORF2 of PCV-2.

52. (New) The method according to any one of claims 40 or 41 wherein the administering includes administering at least one plasmid that contains and expresses ORF1 of PCV-1.

53. (New) The method according to any one of claims 40 or 41 wherein the administering includes administering at least one plasmid that contains and expresses ORF2 of PCV-1.

54. (New) The method of claim 44 wherein the DMRIE:DOPE molar ratio ranges from 95:5 to 5:95.

55. (New) The method of claim 44 wherein the DMRIE:DOPE molar ratio is 1:1.

56. (New) The method of claim 42 wherein the plasmid:DMRIE weight ratio ranges from 50:1 to 1:10.

57. (New) The method of claim 42 wherein the plasmid:DMRIE weight ratio ranges from 10:1 to 1:5.

e1 Cont

58. (New) The method of claim 42 wherein the plasmid:DMRIE weight ratio ranges from 1:1 to 1:2.

59. (New) The method of claim 44 wherein the plasmid:DMRIE-DOPE weight ratio ranges from 50:1 to 1:10.

60. (New) The method of claim 44 wherein the plasmid:DMRIE-DOPE weight ratio ranges from 10:1 to 1:5.

61. (New) The method of claim 44 wherein the plasmid:DMRIE-DOPE weight ratio ranges from 1:1 to 1:2.

62. (New) The method of claim 45 wherein the administering includes administering a plasmid that encodes and expresses a porcine cytokine which is GM-CSF.

63. (New) The method of claim 40 or 41 wherein the administering is intramuscularly.

64. (New) The method of claim 40 or 41 wherein the administering is intradermally.

65. (New) The method of claim 39 wherein the administering is intramuscularly.

66. (New) The method of claim 39 wherein the administering is intradermally.

67. (New) The immunogenic preparation of claim 12 or 13 which is for intramuscular administration.

68. (New) The immunogenic preparation of claim 12 or 13 which is for intradermal administration.--

Please amend the claims without prejudice, without admission, without surrender of subject matter, and without any intention of creating any estoppel as to equivalents, as follows:

18. (Amended) The immunogenic preparation according to any one of claims 12, 13, 15, 16 or 17 further comprising a porcine cytokine or a plasmid that encodes and expresses a porcine cytokine.

e2

20. (Amended) The immunogenic preparation according to claim 12 or 13, further comprising a plasmid encoding and expressing an immunogen from a porcine pathogenic agent other than PCV-2 or PCV-1.

fyi e2 > e3

21. (Amended) The immunogenic preparation according to any one of claims 12, 13, 15, or 16, wherein the preparation includes at least one plasmid that contains and expresses ORF1 of PCV-2.

22. (Amended) The immunogenic preparation according to any one of claims 12, 13, 15, or 16, wherein the preparation includes at least one plasmid that contains and expresses ORF2 of PCV-2.

23. (Amended) The immunogenic preparation according to any one of claims 12, 13, 15, or 16, wherein the preparation includes at least one plasmid that contains and expresses ORF1 and ORF2 of PCV-2.

24. (Amended) The immunogenic preparation according to any one of claims 12, 13, 15, or 16, wherein the preparation includes at least one plasmid that contains and expresses ORF1 of PCV-2 and ORF2 of PCV-2.

25. (Amended) The immunogenic preparation according to any one of claims 12, 13, 15, or 16, wherein the preparation includes at least one plasmid that contains and expresses ORF1 of PCV-1.

26. (Amended) The immunogenic preparation according to any one of claims 12, 13, 15, or 16, wherein the preparation includes at least one plasmid that contains and expresses ORF2 of PCV-1.

39. (Amended) A method for eliciting an immunogenic response in a porcine host against porcine circovirus comprising administering to the porcine host the immunogenic preparation of any one of claim 12, 13, 15 or 16.

Please cancel claims 14, 27, 36 and 38, without prejudice, without admission, without surrender of subject matter, and without any intention of creating any estoppel as to equivalents.